echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The "Science" single domain antibody TB202-3 has shown effective binding to a variety of SARS-CoV-2 strains in preclinical studies, including α, β and γ strains

    The "Science" single domain antibody TB202-3 has shown effective binding to a variety of SARS-CoV-2 strains in preclinical studies, including α, β and γ strains

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Twist Bioscience Corporation reported that the candidate antibody TB202-3 (CoVIC-094) it discovered showed that it can effectively bind to a variety of SARS-CoV-2 mutant strains, including pseudoviruses containing E484K, N501Y, D614G, Y453F and The K417N mutant strain indicates that this therapeutic antibody may be effective against a variety of COVID-19 strains


    The Coronavirus Immunotherapy Alliance (CoVIC) conducted a blind analysis and confirmed that TB202-3 completely blocked the binding of the SARS-CoV-2 spike protein to human ACE2


    CoVIC uses high-throughput surface plasmon resonance analysis and cryo-electron microscopy to classify antibodies that react in the SARS-CoV-2 receptor binding domain (RBD) into 7 different "communities" (RBD-1 to RBD- 7)


    COVID-19 continues to evolve and will cause more mutations and virus strains


    SARS-CoV-2 is an RNA virus


    Dr.


    Dr.


    Previous studies have shown that in the preclinical hamster challenge model, at the minimum dose of 1 mg/kg, the VHH single domain "nanobody" TB202-3 has a protective effect on weight loss, which is a key indicator of disease severity


    About 75% of the antibodies in the blood are IgGs


    On the other hand, VHH single domain recognition target only requires one domain on the heavy chain antibody


    Original search: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.